Renovion Receives Patent Allowance for Novel Therapy
- Patent claims set foundation for commercialization
- Board and management team in place to execute pre-clinical plan
CHAPEL HILL, N.C., February 1, 2016 --Renovion, Inc., a privately-held biopharmaceutical company developing novel therapeutics for respiratory diseases, including lung transplant patients, cystic fibrosis (CF), severe asthma and chronic obstructive pulmonary disorder (COPD), announced today that it has received positive response from the U.S. patent office regarding claims for the company’s lead compound – ARINA-1. These claims set the foundation for the company to move forward with the lead pharmaceutical therapy delivered to the airway of patients via twice daily nebulized treatment. Driven by this patent success, Renovion announced that Dan Copeland has accepted the position of CEO of Renovion. In addition, Fred McCoy, CEO of NeuroTronik, Joe Davis, Managing Partner of DWM Advisors, and Derek Winstanly, MBChB, former Executive VP, Chief Customer and Governance Office at Quintiles, and have taken Board seats.
“We are excited to have received positive news relative to our patent claims, and the expertise reflected in our board ideally position Renovion to rapidly advance our therapy into clinical development. We have seen great results in a small group of patients so far – including lung transplant, cystic fibrosis and severe asthma – and we plan to continue to gather information on ARINA -1 while we execute our pre-clinical plan. We are also interested in learning more about our potential to treat COPD and patients with other lung diseases,” said Dan Copeland, CEO of Renovion. “I welcome our new board members to the Renovion team and look forward to working closely with Fred, Derek and Joe to achieve our mission of delivering disease-modifying therapies for devastating pulmonary diseases.”
Renovion, Inc. was formed in 2013 to leverage a discovery at the University of North Carolina at Chapel Hill that pharmaceutically reduces infection and addresses airway inflammation via a novel therapy – ARINA-1. Renovion is a pre-clinical stage pharmaceutical company with a therapy for chronic inflammatory airway diseases. Our goal is to be the first drug ever approved for patients who have received a bilateral lung transplant.
“Unlike other solid organ transplants, the rate of survival has remained the same for lung transplant over the last 15 years with a five year survival rate of 60% and a ten year survival of just 20% - this is the lowest for all solid organ transplants. There is a great need for therapies able to alter the course of disease for this group of 10,000 patients. We believe Arina-1 can be that therapy,” said Copeland. “After success in these patients, we want to help patients in other areas such as CF, asthma and COPD.”
Renovion, Inc. is developing inhaled therapeutics designed to address both inflammation and infection in the airway. The Company’s development efforts are based on a decade of research and discoveries at UNC-Chapel Hill. The company is currently in the pre-clinical stage and is unique in that the product has shown antibacterial and anti-infective impact in patients. Renovion has completed a successful pre-IND meeting with the FDA and plans to proceed rapidly to completing pre-IND milestones to establish lung transplant as our first indication. After this success we will expand to other therapeutic areas including CF, COPD and asthma. Further information regarding Renovion is available at www.renovion.com.
Dan Copeland, CEO
Source: Renovion, Inc.